I was recently asked by a client about some articles she found describing a new canine cancer vaccine and she wanted to know more about it.
There have been several news stories recently discussing this topic and I thought it would be helpful to Dogington Post readers to explain these developments.
Most of the articles tell the story of a human medical oncologist from Australia that is working with veterinarians on a process to take tumor cells from a dog with cancer and create a vaccine. This requires removal of tumor tissue, processing the proteins, combining them with a benign bacteria, and creating a vaccine for the treatment of the cancer. The vaccine is then injected into the dog that the tumor was removed from.
The result is that the immune system is stimulated to attack the cancer cells in the dog’s body. In some dogs, this has been effective at slowing cancer growth or even caused remission in some dogs.
The research is being closely watched by human cancer researchers and is most likely well funded due to it’s likely application in human medicine:
The vaccine, developed by researchers at Sydney’s Kolling Institute, has been trialled on almost 30 dogs with advanced melanoma, bone cancer and liver cancer.
The results of the early trial have not been published in a scientific journal because researchers want to patent the vaccine technology first.
Medical oncologist at the Royal North Shore Hospital, Professor Stephen Clarke, hopes that human clinical studies will start in six months to one year. Source
This is not as surprising as it may sound as the technology has been around for some time. Veterinarians have been pursuing this concept with canine lymphoma for almost 20 years and a melanoma vaccine from Merial was approved for use in 2010.
Most of us think of vaccines as useful for prevention of infectious disease. This type of vaccine is considered a therapeutic vaccine and is designed to program the dog’s immune system to help fight cancer.
The melanoma vaccine is well tolerated by dogs with few side effects reported. It is only available through veterinary oncologists . These professionals are able to help fur parents decide if it is an appropriate treatment for each individual dog. There are some successes and some failures, as noted by this veterinary oncologist:
The aggressive nature of melanoma in dogs and short survival times after surgery emphasize the importance of developing an effective therapy for prevention of spread of this cancer. Ramos-Vera et al (Vet Pathol 2000) reported in a retrospective study of 388 dogs with melanoma in the mouth that the average survival time after surgery was only 173 days (<6 months). Published studies evaluating the survival times in dogs with melanoma in the mouth undergoing surgery and treatment with the Merial melanoma vaccine report average survival times of 599 days (20 months) or longer (Bergman et al Vaccine 2006; Grosenbaugh et al. AJVR 2011). These results, though not from randomized studies, are promising and have prompted many Veterinary Oncologists to recommend the vaccine for patients with stage 2 and 3 melanoma despite the lack of FDA-standard clinical trials. The vaccine is well tolerated and has not been reported to be associated with side effects requiring medical intervention. Source
Researchers continue to work to improve and extend the lives of our furry friends through new technology and understanding of disease. Since there are so many different types of cancer, no one has been able to find a cure but more progress is made every day.
If your dog has melanoma and you would like to find out more about the vaccine, see the following resources: